News

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near

10/09/2024

AMPEL BioSolutions: Precision Medicine Blood Testing Predicts Heart Disease and Therapeutic Intervention

AMPEL BioSolutions announced a precision medicine blood test that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.  Inflammatory and immune system abnormalities identified in the blood of individuals predisposed to heart disease by AMPEL two years ago were confirmed and extended in the peer-reviewed Cell iScience paper announced

10/02/2024

Afton Scientific to Expand Biopharmaceutical Facility in Albemarle County

Governor Glenn Youngkin announced that Afton Scientific, a manufacturer of sterile injectable pharmaceuticals, will invest over $200 million to expand its biopharmaceutical manufacturing facility in Albemarle County. The project will create hundreds of new jobs. Virginia successfully competed with several states for the project. “Afton Scientific’s multi-million dollar expansion in Albemarle County is a powerful testament

10/01/2024

Governor Glenn Youngkin Announces Over $2.5 Million in Growth and Opportunity Virginia Grants

Governor Glenn Youngkin today announced more than $2.5 million in Growth and Opportunity for Virginia (GO Virginia) grant awards for 21 projects focused on creating workforce pipelines for targeted industries and supporting the cultivation of critical industry resources to attract and grow Virginia-based businesses. “GO Virginia enables us to make strategic investments in pivotal projects

09/30/2024

AgroSpheres Secures $37M Series B Funding – Pushes for Growth

AgroSpheres Inc. (AGS), a biotechnology leader in sustainable crop protection and crop health, today announced the final close of a $37 million Series B funding round led by Zebra Impact Ventures, which invests through the Regenerative Growth I strategy, run in partnership with Mirabaud Asset Management. The round also saw strong participation from existing investors

09/23/2024

Caretaker Partners with Red One Medical to Expand Advanced Monitoring to More Veterans and Hospital Departments

Caretaker Medical and Red One Medical have partnered to enable safer healthcare for U.S. veterans at VA hospitals. Caretaker’s VitalStream® will offer VA medical centers the ability to continuously and non-invasively monitor blood pressure, cardiac output, stroke volume, fluid responsiveness and other advanced hemodynamic parameters throughout all hospital departments. This level of monitoring has been

09/23/2024

ReAlta Life Sciences Announces First Patient Dosed in Phase 2 Study Evaluating RLS-0071 for the Treatment of Steroid-Refractory Acute Graft-versus-Host Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that the first patient has been dosed in its Phase 2 study of RLS-0071, the Company’s lead therapeutic candidate, for the treatment of hospitalized patients with

09/19/2024

Nasoni Takes the Lead in Transforming Care for Alzheimer’s and Dementia Patients with $2.4M Federal Grant

Hampton Roads stands at the forefront of innovation by announcing a $2.4 million federal grant to enhance care for Alzheimer’s and dementia patients. This funding, spearheaded by Congresswoman Jen Kiggans, not only highlights the region’s commitment to healthcare but also emphasizes the role of local startups like Nasoni, which are driving the future of patient

09/19/2024

Children’s National Hospital selected to lead next-generation BARDA Accelerator Network Special Populations Hub

Children’s National Hospital, widely recognized for its expertise and innovation in pediatric care, has been chosen by the Biomedical Advanced Research and Development Authority (BARDA) to lead the Special Populations Hub in the next generation of the BARDA Accelerator Network. BARDA, is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

09/19/2024

Project providing clean manufacturing space comes to Roanoke

Three Southwest Virginia biomedical companies that need sterile space for manufacturing will be part of a modular cleanroom pilot program. A $100,000 grant from economic development initiative GO Virginia and $221,500 in non-state money will fund the project, according to a GO Virginia news release. Cancer-fighting businesses Tiny Cargo Co. and Acomhal Research, both in

09/18/2024

Virginia Governor Glenn Youngkin named BIO’s Governor of the Year

Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award. BIO’s annual award honors governors for their leadership and commitment to strengthening biotechnology in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle. “Investing

09/17/2024

Activation Capital Launches Start-the-Journey: Pre-Accelerator Program

Activation Capital proudly announces the launch of Start-the-Journey, a new BioHealth Pre-Accelerator designed to equip early-stage biotech and life science entrepreneurs with the knowledge and tools to build successful startups. Powered by Fat Robin Consulting, this innovative program supports founders in the initial phases of their entrepreneurial journey, preparing them for more advanced initiatives like

09/13/2024

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only twice-a-year, healthcare professional

09/13/2024

VaLogic Bio Acquires Facility Logix to Expand Life Sciences Facility Services

VaLogic Bio, a platform company of 424 Capital and a leading provider of compliance and SaaS services to the life sciences industry, proudly announces the acquisition of Facility Logix (FLGX), a renowned firm specializing in planning, developing, and project management for life sciences facilities. This acquisition aligns with VaLogic Bio’s strategic vision to enhance its

09/12/2024

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States. Tecentriq Hybreza can be injected subcutaneously over approximately

09/12/2024

ATCC Expands Campus with a New Biomanufacturing Facility in Prince William County

Governor Glenn Youngkin today announced that American Type Culture Collection will invest $54.7 million to expand its bioresource center campus in Prince William County with a new biomanufacturing facility focused on global health. ATCC is a private, nonprofit global biological resource center and standards organization that provides scientists with the biomaterials and resources they need

09/10/2024

Biotech startup with strong VCU ties wins prestigious state grant for its DNA analysis tool

A startup company with roots at Virginia Commonwealth University has received a prestigious state grant that will accelerate its work in advancing DNA analysis. Now housed in incubator office space in the Richmond neighborhood of Scott’s Addition, Evizia is building on more than a decade of published research and grants tied to its husband-and-wife co-founders

09/06/2024

NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines

NImmune Biopharma (“NImmune”), a late-clinical-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics, today announced a research collaboration with BioTherapeutics, Inc. (“BioTherapeutics”), a clinical-stage biotech company that combines advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products. The collaboration strengthens NImmune’s precision immunology capabilities by providing

09/06/2024

Canon Virginia, Inc. to Expand Newport News Facility

Governor Glenn Youngkin announced that Canon Virginia, Inc., a leading global manufacturer of consumer and office products, will expand its manufacturing facility in the City of Newport News. The expansion will support Canon’s new initiative to scale a unique method of isolating natural silk protein to create a solution with applications for multiple industries. Canon

09/05/2024

AgroSpheres Receives EPA Approval of First AgriCell Powered Biofungicide

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, today announced that its first biofungicide, powered by the novel AgriCell technology, has received approval from the Environmental Protection Agency (EPA) following a comprehensive review. This approval allows the company to commence commercial production, bringing its innovative bioplatform technology directly to growers. The proprietary

09/04/2024

LumaCyte Unveils Predictive CAR T Donor Analytics to Revolutionize Cell Therapy Manufacturing

LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for predictive CAR T donor analytics. Leveraging its novel Laser Force Cytology™ (LFC™) technology and Radiance® instrument, LumaCyte uncovers deep data insights into highly variable and complex patient and donor cellular starting material, enabling cell

09/04/2024

ReAlta Life Sciences Further Bolsters Experienced Executive Team with the Appointment of Peter Ho, Ph.D., as Head of Business Development and Corporate Strategy

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that Peter Ho, Ph.D., has joined the Company as Head of Business Development and Corporate Strategy. “I am thrilled to have Peter join our executive team

08/29/2024

Activation Capital Selects 10 Startups for Inaugural Frontier BioHealth Program

Activation Capital, an innovation ecosystem development organization, has announced the selection of 10 fast-growing startups from across the country for the inaugural Frontier BioHealth program, which commenced with an in-person gathering on August 8-9, 2024. Each company will benefit from highly specialized training, targeted mentorship, and extensive relationship-building opportunities to accelerate its growth in the life

08/22/2024

ReAlta Life Sciences Invigorates Executive Team with Appointments of David Marek as Chief Executive Officer and Paolo Martini, Ph.D., as Chief Research and Development Officer

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced two distinguished biopharmaceutical veterans to lead the Company: David Marek appointed as Chief Executive Officer and Paolo Martini, Ph.D., appointed as Chief Research and Development